Skip to main content
News

Single daily pill shows promise as replacement for complex, multi-tablet HIV treatment regimens

A phase 3 clinical trial, led by Professor Chloe Orkin of Queen Mary University of London, has shown that a new, daily oral tablet that combines two current HIV treatment medications – bictegravir and lenacapavir (BIC/LEN) – may simplify treatment significantly for people with HIV who currently take very complex treatments.

Published on:

For media information, contact:

Press Office
email: press@qmul.ac.uk
Back to top